Showing results (481-490 of 584) with videos related to
Sort By:
Pageof 59
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|January 10, 2016
Detection of ECG effects of (2R,4R)-monatin, a sweet flavored isomer of a component first identified in the root bark of the Sclerochitin ilicifolius plantBorje Darpo, Thorir D Bjornsson, Witty A Brathwaite, et al.JCI Insight|August 30, 2019
Precocious neuronal differentiation and disrupted oxygen responses in Kabuki syndromeGiovanni A Carosso, Leandros Boukas, Jonathan J Augustin, et al.JCI Insight|September 16, 2025
In utero rescue of neurological dysfunction in a mouse model of Wiedemann-Steiner syndromeTinna Reynisdottir, Kimberley J Anderson, Katrin Möller, et al.Nature|March 26, 2026
CO<sub>2</sub> subsurface mineral storage by its co-injection with recirculating waterEric H Oelkers, Serguey Arkadakskiy, Zeyad Ahmed, et al.Journal of Thrombosis and Thrombolysis|February 20, 2017
Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trialAlma Rut Oskarsdóttir, Brynja R Gudmundsdottir, Olafur S Indridason, et al.Chemical Science|August 18, 2023
Comprehensive structural, infrared spectroscopic and kinetic investigations of the roles of the active-site arginine in bidirectional hydrogen activation by the [NiFe]-hydrogenase 'Hyd-2' from <i>Escherichia coli</i>Rhiannon M Evans, Stephen E Beaton, Patricia Rodriguez Macia, et al.Journal of Medical Genetics|December 6, 2018
Kabuki syndrome: international consensus diagnostic criteriaMargaret P Adam, Siddharth Banka, Hans T Bjornsson, et al.The Lancet. Haematology|December 22, 2015
Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trialPáll T Onundarson, Charles W Francis, Olafur S Indridason, et al.Journal of Clinical Pharmacology|September 16, 2003
A review and assessment of potential sources of ethnic differences in drug responsivenessThorir D Bjornsson, John A Wagner, Stephen R Donahue, et al.Pharmacogenetics and Genomics|March 10, 2016
HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injuryPaola Nicoletti, Anneke N Werk, Ashley Sawle, et al.Pageof 59